LEUVEN, Belgium, May 10, 2012 /PRNewswire/ -- Regulated Information Disclosure in accordance with the law of May 2, 2007 ThromboGenics NV (Euronext

LEUVEN, Belgium, April 17, 2012 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines,

LEUVEN, Belgium, April 13, 2012 /PRNewswire/ -- ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic

LEUVEN, Belgium, March 29, 2012 /PRNewswire/ -- ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic

LEUVEN, Belgium, March 16, 2012 /PRNewswire/ -- ThromboGenics to concentrate on realizing ocriplasmin's significant commercial